Author:
Villegas RI,Melo-Durán S,Cevallos A,Barros-Prieto EA
Reference32 articles.
1. Francis MD, Valent DJ. Historical perspectives on the clinical development of bisphosphonates in the treatment of bone diseases. J Musculoskelet Neuronal Interact [Internet]. 2007; 7(1): 2-8. Available in: http://www.ncbi.nlm.nih.gov/pubmed/17396000
2. Smith R, Russell RGG, Bishop M. Diphosphonates and Paget\\\'s disease of bone. Lancet. 1971; 297(7706): 945-7.
3. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc [Internet]. 2008; 83(9): 1032-45. Available in: http://www.ncbi.nlm.nih.gov/pubmed/18775204
4. Papapoulos SE, Quandt SA, Liberman UA, Hochberg MC, Thompson DE. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int [Internet]. 2005; 16: 468-74. Available in: http://link.springer.com/10.1007/s00198-004-1725-z
5. Giger EV, Castagner B, Leroux JC. Biomedical applications of bisphosphonates. J Control Release. 2013; 167(2): 175-88.